Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100
Guggenheim analyst Yatin Suneja maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $69 to $100.
Stocks · News reference
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ProMIS Neurosciences Inc. (PMN)
Filed: 2026-08-13 AccNo: 0001104659-26-095905 Size: 246 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate
ProMIS Neurosciences (NASDAQ:PMN) reported quarterly losses of $(1.28) per share which beat the analyst consensus estimate of $(1.38) by 7.25 percent. This is a 82.34 percent increase over losses of $(7.25) per share